Efficacy and safety of multiple-dose oritavancin therapy for treatment of complicated infectious diseases.

Trial Profile

Efficacy and safety of multiple-dose oritavancin therapy for treatment of complicated infectious diseases.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Oritavancin (Primary)
  • Indications Bacteraemia; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Nov 2017 New trial record
    • 09 Nov 2017 Results assessing efficacy and safety of multiple-dose oritavancin therapy for treatment of complicated infectious diseases, were published in the Pharmacotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top